20 August 2018
Visiongain’s new report Global Allergic Rhinitis Drugs Market 2017-2027: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines indicates that the global allergic rhinitis market will see $13.9bn in spending in 2021.
The global allergic rhinitis drugs market is expected to grow at a CAGR of 3.2% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.3% from 2016-2027. The market is estimated at $11.9bn in 2016 and $13.9bn in 2021.
The lead analyst of the report said: “The global market for allergic rhinitis drugs was valued at $11.9bn in 2016. Oral antihistamines accounted for 39.9% of the total market in 2016. We expect this segment of the market to maintain its place as the leading segment within the market over the forecast period.
The rise of immunotherapy will be most noticeable in the US and Asia-Pacific markets during the forecast period, helping to meet increasing demand for allergic rhinitis treatments due to the expected global increase in the prevalence of allergic rhinitis. The allergic rhinitis drugs market will grow at a slow rate as initial declines in the oral antihistamine and intranasal corticosteroid segments are offset by growth in other areas, notably immunotherapy.”
The 255-page report contains 85 tables and 88 figures that add visual analysis in order to explain the developing trends within the Global Allergic Rhinitis Drugs Market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines.
This report also provides revenue forecast for 27 leading products in the allergic rhinitis drugs market.
The 255-page report offers market forecasts for the US, Germany, UK, France, Italy, Spain, China, Japan, India, Russia, Brazil and Rest of the World.
This report discusses the trends and development in the allergic rhinitis pipeline. Moreover, our work provides analysis and sales forecast of the leading companies in the allergic rhinitis drugs market.
The report Global Allergic Rhinitis Drugs Market 2017-2027: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines report will be of value to anyone who wants to better understand the allergic rhinitis drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the allergic rhinitis drugs market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.
30 September 2020
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.
28 September 2020
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.